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Abstract The aim of this project was to evaluate the ice-
water test as a predictor of the response to intradetrusor bot-
ulinum toxin injection in patients with neurogenic detrusor
overactivity. We retrospectively evaluated the urodynamic
parameters in 22 patients with neurogenic bladder dysfunc-
tion and positive ice-water test. Maximum cystometric
capacity (MCC), reXex volume (RV), maximum detrusor
pressure during voiding (MVP) and bladder compliance
(BC) were compared before and after intradetrusor injec-
tion of 300 units botulinum toxin and calculated as a quo-
tient. The ice-water test was performed before the injection,
and the maximum pressure rise and the time to maximum
pressure were measured. Furthermore, the ratio between
maximum pressure and time to reach maximum pressure
was calculated as the velocity of pressure rise. Correlations
between the ice-water test criteria and the quotients of the
cystometric data before and after injection were determined
by the Spearmen’s Rho coeYcient. The increase in MCC
and RV after botulinum toxin A injection showed a small
positive, but insigniWcant correlation of 0.25 and 0.2 to the
velocity of pressure rise of the ice-water test. A small nega-
tive, but insigniWcant correlation was found in change of
BC and MVP with ¡0.17 and ¡0.2, respectively. Based on
our population the ice-water test cannot predict the eYcacy
of intradetrusor botulinum toxin injections in patients with
neurogenic detrusor overactivity.
Keywords Botulinum toxin type A · Neurogenic bladder · 
Outcome assessment (health care) · Urodynamics
Introduction
In the last years several studies demonstrated that botu-
linum toxin A injection into the detrusor muscle is a safe
and valuable treatment of neurogenic incontinence due to
detrusor overactivity [1–3]. A dose of 300 international
units is needed to counteract an overactive detrusor.
Schurch et al. [1], showed a high rate of complete conti-
nence and satisfaction, a signiWcant increase in reXex vol-
ume (RV) and maximum cystometric bladder capacity and
a signiWcant decrease in maximum detrusor voiding pres-
sure in spinal cord injured patients with incontinence resis-
tant to anticholinergic treatment. Recently, the safety and
eYcacy of the treatment have been conWrmed in a random-
ized placebo-controlled study [4].
However, not all patients respond to the treatment; the
duration of eYcacy ranges considerably from 6 to
12 months, some patients become fully continent while oth-
ers do not, and rarely do the patients become resistant after
repeat injection. Reasons for a variable response are
unknown and a test to predict the response to the treatment
would be of value to distinguish between potential respond-
ers and nonresponders before injection.
In this study we evaluated urodynamic criteria before
and after intradetrusor injections of botulinum toxin and
hypothesized that the urodynamic ice-water test can be
used as a predictive factor for the response to the treatment.
Methods
Patients
A total of 22 patients (13 women and 9 men, mean age of
42.5 years (range 15–70 years) who had received an
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in our institution were included in this study. The neuro-
genic bladder dysfunction was due to paraplegia in ten
cases, tetraplegia in four cases, multiple sclerosis in Wve
cases and nontraumatic spinal lesions in three cases. Indica-
tions for injecting the detrusor muscle with botulinum toxin
A were: neurogenic incontinence or side eVects of anticho-
linergic medication, which led to the discontinuation of the
therapy. Patients with serious concomitant illness and preg-
nant or breast-feeding women, were excluded. Seventeen
patients were on clean intermittent catheterization and Wve
on indwelling catheter (suprapubic or transurethral).
Urodynamic assessment and toxin injection
Complete urodynamic assessment was performed in every
patient before and after the application of botulinum toxin
type A according to the standards of the International Con-
tinence Society [5]. The ice-water test was carried out prior
to the therapy. The follow-up examination was done on the
maximum eVect of botulinum toxin A with a mean after
3 months (range 1–8 months).
At the beginning of the urodynamic measurement base-
line an ice-water test was performed. With the patient
supine, water at 4°C was instilled as quickly as possible
through a 12 Fr catheter at 100 ml/min, using a maximum
volume of 200 ml. Instillation was stopped before the maxi-
mum volume when the patient showed a leakage or got
autonomic dysreXexia. Bladder and urethral pressures were
measured by a second microtransducer after correct placing
under radiologic guidance. Intraabdominal pressure was
recorded simultaneously intrarectally to exclude artefacts.
The test was considered positive if a phasic detrusor
contraction >30 cmH2O was recorded or a Xuid expulsion
beside the catheter occurred. A detrusor pressure of
30 cmH2O was taken as cutoV value, similar to that used by
Geirsson et al. [6]. For the baseline and follow-up urody-
namic assessments the following parameters were specially
determined: maximum cystometric capacity (MCC), reXex
volume (RV), maximum detrusor pressure during voiding
(MVP) and bladder compliance (BC). Maximum cystomet-
ric capacity was deWned as the volume at which involuntary
voiding occurred or in the absence of involuntary voiding
when the Wlling was stopped, usually done at 500 ml. ReXex
volume corresponded to the infused volume at the start of
the Wrst reXex detrusor contraction during Wlling cystome-
try. Without involuntary voiding maximum detrusor pres-
sure during voiding was assigned as the maximum pressure
during the reXex detrusor contraction. Finally, BC was cal-
culated as the change in volume divided by the change in
detrusor pressure at MCC or immediately before the start of
a reXex detrusor contraction that causes signiWcant leakage.
A total dose of 300 units of botulinum toxin type A
(Botox®, Allergan Inc.) were injected into the detrusor
muscle under cystoscopic control. The total dose of 300
units was distributed over 30 injection sites in the bladder
(10 units and 1 ml per site) sparing the trigone. A normal
rigid 22 FF cystoscope and a Xexible 7 FF injection needle
were used.
Data analysis
The urodynamic parameters MCC, RV, MVP and BC after
injection (at maximum eVect) were compared to the base-
line values. Statistical analysis was performed by paired t
test, signiWcance considered at P < 0.05. The urodynamic
parameters after treatment were also divided by the corre-
sponding parameter before treatment to calculate a quo-
tient.
During the ice-water test maximum pressure rise and
time to maximum pressure were measured. Maximum
detrusor pressure during ice-water test was divided by the
time to reach maximum detrusor pressure; this quotient
(velocity of pressure rise) was taken as the degree of posi-
tivity of the test (Fig. 1). Correlations between the criteria
of the ice-water test and quotients of the urodynamic
parameters were evaluated by Spearmen’s Rho coeYcient
calculation.
Results
All 22 patients have well tolerated the injection of botu-
linum toxin A, no complications or toxin related side eVects
were reported. At the follow-up examination only two
patients reported no improvement of the incontinence, three
reported a reduction of the incontinence episodes and all
other patients were continent. Of the patients who took
anticholinergic drugs before treatment, 13% could reduce
Fig. 1 Maximum pressure rise and time to maximum pressure during
the ice-water test as a quotient determining the velocity of pressure,
which was interpreted as the degree of positivity123
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gic medication after the injection.
Urodynamic evaluation showed a signiWcant increase in
mean MCC from 259 ml to 332 ml (P < 0.05) and a signiW-
cant increase in mean RV from 187 to 287 ml (P < 0.001).
There was a signiWcant decrease in mean MVP before and
after treatment from 76 to 37 cmH20 (P < 0.01). Mean BC
increased markedly but not signiWcantly from 36 to 73 ml/
cmH2O (P = 0.22). The mean calculated quotient (parame-
ter after treatment divided by parameter before treatment)
was 1.6, 2.0, 0.6 and 5.8 for MCC, RV, MVP and BC,
respectively.
Mean maximum detrusor pressure during ice-water test
was 98 cmH2O (range 34–240), mean time to reach this
maximum detrusor pressure amounted 97 s (range 42–
210 s). The mean velocity of pressure rise of the ice-water
test was 1.15 cmH2O/s ranged from 0.23 to 3.
The increasing MCC after injection of botulinum toxin
A showed a small positive, but insigniWcant correlation of
0.25 to the velocity of the ice-water test (Fig. 2). So did the
change in RV with 0.2 (Fig. 3). We observed a small nega-
tive, but insigniWcant correlation between change of MVP
(Fig. 4) and BC (Fig. 5) during voiding with ¡0.2 and
¡0.17, respectively.
Discussion
The ice-water test was Wrst described by Bors and Blinn in
1957; they reported that rapid Wlling of the bladder with
ice-water leads to an immediate detrusor contraction in
patients with an upper motor neuron lesion. Patients with a
lower motor neuron lesion and neurologically normal per-
sons showed no detrusor response [7]. In the study on cats,
Fall et al. [8] observed a spinal micturition reXex to cold
water which is carried by type C unmyelinated Wbres in
contrast to the micturition reXex normally mediated from
mechanoreceptors by aVerent A delta Wbres. By activation
of the bladder-cooling reXex, elicited from cold receptors in
the bladder wall, a positive ice-water test is considered as a
primitive reXex, like the Babinski reXex. The reXex is pres-
ent at birth and then suppressed during nerval growth under
inhibitory control at approximately 4 years. Some authors
recommend the routine use of the ice-water test in the uro-
dynamic evaluation because a positive test indicates a neu-
rological lesion and is always negative in normal subjects
[9, 10].
In recent years the test was evaluated in several studies
of neurogenic bladder dysfunction and the diagnostic value
was extended. So in a study by Geirsson et al., a positive
Fig. 2 Correlations between maximum bladder capacity before and
after treatment and ice-water test criteria
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Fig. 3 Correlations between reXex volume before and after treatment
and ice-water test criteria
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Fig. 4 Correlations between voiding pressure before and after treat-
ment and ice-water test criteria
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Fig. 5 Correlations between compliance before and after treatment
and ice-water test criteria
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with central spinal lesions and in about 75% of the patients
with overactive bladder associated with the three common
neurological disorders multiple sclerosis, Parkinsonism and
vascular-origin hemiplegia [11]. On the other hand, the test
was always negative in patients with various disorders of
micturition but no neurological lesions [10]. Moreover a
positive ice-water test not only supports the diagnosis of a
neurological disorder, it also has an important role of an
early recognition of a neurological disease, especially in
those patients with micturition disorders that are diYcult to
interpret [12]. In patients with multiple sclerosis a positive
ice-water test can give strong evidence for spinal cord
involvement, especially when it is associated with detrusor-
sphincter dyssynergia [13]. That is the reason why we
always perform an ice-water test as part of the Wrst urody-
namic assessment in our institution, particularly because it
is simple to carry out.
Other studies focused on the incidence of a positive ice-
water test in bladder outlet obstruction with controversial
results. Chai et al. [14] reported a signiWcantly higher inci-
dence of a positive ice-water test compared to the unob-
structed controls, Hirayama et al. [15] found similar results
concerning bladder outlet obstruction. This observation
could not be conWrmed in another study of 16 patients with
obstruction. Only one of these patients had a positive blad-
der-cooling test [16]. The above-mentioned assessments
use diVerent cutoV pressure values for a positive ice-water
test. These conXicting results indicate the importance of a
standardized performed test. For our data we considered the
test to be positive when a detrusor contraction of
>30 cmH2O with or without Xuid leakage was reported, as
recommended by Geirsson et al. [6], based on the determi-
nation of the critical pressure in a large group of patients. In
their work, Geirsson et al. [6] also showed that both the
infusion speed and the infused volume were not decisive
for the outcome of the test provided that the bladder was
suYciently cooled.
Most of the spinal cord injured, myelomeningocele and
multiple sclerosis patients with neurogenic overactive blad-
der can be categorized as upper motor neuron dysfunction.
Standard treatment options contain clean intermittent self-
catheterization and oral anticholinergic drugs to achieve
continence. These drugs have relevant side eVects and may
often not restore continence. Botulinum toxin injections
into the detrusor were introduced in spinal cord injured
patients in 1997 [1, 2]. The preliminary results showed that
this therapeutic option could signiWcantly improve subjec-
tive (satisfaction) and objective (urodynamic and degree of
incontinence) parameters. In the recent years both retro-
spective studies with large patient numbers as well as pro-
spective, randomized, placebo-controlled trials conWrmed
the preliminary data [3, 4]. The present study with 22
patients could also show a clear improvement of inconti-
nence after injection of 300 units botulinum toxin A into
the detrusor. So did the objective urodynamic parameters;
we evaluated a signiWcant increase in mean MCC and RV
and a signiWcant decrease in mean MVP. The data did not
vary much compared to the previous studies.
Until now neither the severity of incontinence nor the
objective urodynamic parameters could predict the eVect of
the intradetrusal injection of botulinum toxin although there
is some evidence that the severity of detrusor overactivity
and the method of voiding may have some bearing on treat-
ment eVect [17]. Usually, patients can be classiWed into
responders and non-responders only after the intervention.
Our study focused on the question if the eYcacy of botu-
linum toxin A can be predicted based on an objective, stan-
dardized urodynamic test like the ice-water test. Geirsson
[6], found a clear correlation between maximum detrusor
pressure obtained by bladder cooling and maximum cysto-
metric voiding pressure in patients with a positive but no
correlation in those with a negative bladder cooling test. On
the other hand in most studies concerning the ice-water test
only the qualitative result of the test was taken into account
[10, 13, 18] and compared to other factors. Besides the
maximum detrusor pressure during ice-water test we evalu-
ated additionally the time to reach this maximum pressure.
The quotient of these two parameters was taken as the
velocity of pressure rise representing the degree of positiv-
ity of the ice-water test. Although we could not detect clear
correlations between the parameters of the pre-treatment
ice-water test and the change in urodynamic parameters
after injection of botulinum toxin A, we could identify
some trends. The more positive the bladder cooling reXex
is, the larger increase in MCC and RV and the larger
decrease in MVP can be expected after the injection. Since
there is some evidence to show that both aVerent and eVer-
ent eVects are involved in the mechanism of action of botu-
linum toxin on the detrusor [19, 20] the lacking of clear
positive correlations between the ice-water test criteria and
the calculated quotients of the cystometric data before and
after botulinum toxin can possibly be explained. We cannot
interpret the negative correlation for the change in BC as it
is probably related to the diYculty in calculation in small
capacity bladders.
Conclusions
In the past years botulinum toxin A injections into the
detrusor were shown to be a useful therapy in patients with
neurogenic incontinence. Like the previous studies we
could also Wnd a signiWcant subjective and objective
improvement in our patient group. The ice-water test repre-
sents an important diagnostic tool in urodynamic assess-123
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eVect of the intradetrusal botulinum toxin A injection in
patients with neurogenic detrusor overactivity, it can not be
recommended until now based on the results of our study
with 22 patients. Further studies with a larger patient group
are required to evaluate the importance of the bladder-cool-
ing test as a predictor for therapeutic options.
ConXict of interest Professor Schurch has a consultant agreement
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